125 related articles for article (PubMed ID: 21365623)
1. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
Cancer; 2011 Sep; 117(17):3963-71. PubMed ID: 21365623
[TBL] [Abstract][Full Text] [Related]
2. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
3. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
6. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Hussain M; Goldman B; Tangen C; Higano CS; Petrylak DP; Wilding G; Akdas AM; Small EJ; Donnelly BJ; Sundram SK; Burch PA; Dipaola RS; Crawford ED
J Clin Oncol; 2009 May; 27(15):2450-6. PubMed ID: 19380444
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
12. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
13. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
15. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Qu YY; Dai B; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Ma CG; Yang WY
Asian J Androl; 2013 Jan; 15(1):110-5. PubMed ID: 23147466
[TBL] [Abstract][Full Text] [Related]
17. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Sonpavde G; Periman PO; Bernold D; Weckstein D; Fleming MT; Galsky MD; Berry WR; Zhan F; Boehm KA; Asmar L; Hutson TE
Ann Oncol; 2010 Feb; 21(2):319-324. PubMed ID: 19633050
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]